DSIP complete guide

DSIP — Delta Sleep-Inducing Peptide — is a 9-amino-acid peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter code WAGGDASGE). It was originally isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during electrically-induced delta-sleep states [1]. The compound takes its name from the original observation: research-animal models showed circulating DSIP levels rising during delta-wave sleep, and transferred plasma fractions from delta-sleep animals induced delta-EEG-pattern sleep in recipient animals.

DSIP is one of the older neuropeptide research compounds — its 1970s discovery places it adjacent to the early-tuftsin and ACTH-fragment research lines from which Selank and Semax later emerged. The DSIP published corpus is fragmented but real, spanning slow-wave-sleep architecture, circadian-rhythm modulation, HPA stress-axis regulation, antioxidant and neuroprotective endpoints. Despite the name, the consensus mechanism after decades of research is that DSIP is more accurately a multi-system modulator of brain bioelectric activity than a primary sleep-inducing factor; the original “delta sleep-inducing” label reflects the historical isolation assay rather than a single resolved receptor pathway.

Quick reference — DSIP identifiers

Property	DSIP
Class	Synthetic nonapeptide neuromodulator
Peptide sequence	WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, 9 aa)
Molecular formula	C35H48N10O15
Molecular weight	848.81 g/mol
CAS	62568-57-4
Origin	Originally isolated from rabbit cerebral venous blood during delta-sleep states (Schoenenberger & Monnier, 1977); now produced synthetically
Plasma half-life	Research models: short, ~7–15 minutes
Vial strengths (TogoPeptide)	5 mg lyophilized; also part of the Cognitive Stack

Origin and structure — discovery during delta-sleep states

The DSIP discovery is a small landmark in 20th-century neuropeptide research. In 1977, Guido Schoenenberger and Marcel Monnier at the University of Basel were investigating whether the EEG state of sleep could be transferred between research animals via a humoral factor. Their experimental design was unusual: rabbits were subjected to electrical stimulation of the intralaminar thalamic nuclei, a brain region whose stimulation induces delta-wave (slow-wave) sleep states. Cerebral venous blood was then collected from these donor animals and transfused into recipient rabbits.

The result was reproducible — recipient rabbits developed delta-sleep-like EEG patterns after receiving the donor blood fraction. Subsequent fractionation and sequencing identified the active component as a 9-amino-acid peptide with the sequence WAGGDASGE [1]. Schoenenberger and Monnier named the compound Delta Sleep-Inducing Peptide after the original observation.

The historical context matters. In the 1970s, most neuropeptide discoveries came from tissue extraction — researchers macerated brain or pituitary tissue, fractionated the extract and assayed each fraction for receptor binding or biological activity. DSIP was identified through a functional, transferable EEG-modifying assay instead: a humoral factor active in living recipient animals. That methodological choice is what defined the original “delta sleep-inducing” framing — the peptide was characterised by what it did to recipient EEG patterns, not by what receptor it bound.

Subsequent decades of research did not fully confirm DSIP as a primary sleep-inducing factor. The original 1977 EEG-transfer effect has been variably reproduced across labs and research designs, and DSIP does not bind a single well-characterised sleep-receptor system. What the cumulative published literature has established instead is DSIP’s role as a modulatory neuropeptide with broader multi-system effects — sleep architecture, circadian rhythm, stress-axis, neuroprotection — rather than as a single-purpose hypnotic factor.

Mechanism — multi-system neuromodulator

DSIP’s research footprint spans slow-wave-sleep architecture, circadian-rhythm, HPA stress-axis, antioxidant / neuroprotective and anti-convulsant literature. The mechanism is not single-pathway and does not reduce to a single well-characterised receptor system. The published corpus documents DSIP acting on multiple converging systems with effects that have varied across labs and research designs.

Slow-wave sleep modulation

Published research documents DSIP effects on EEG delta-wave power and sleep-spindle architecture in research-animal models. This is the original research line from the 1977 isolation assay and the most-investigated DSIP endpoint in the published corpus [5]. The mechanism is not fully resolved at the receptor level — DSIP does not bind a single well-characterised receptor system. Multiple research lines suggest indirect modulation via other neuropeptide systems, including somatostatin, opioid and serotonin pathways, rather than direct hypnotic-receptor activation.

Circadian rhythm research

A separate DSIP research line documents diurnal variation in endogenous DSIP levels in research-animal cerebrospinal-fluid samples, plus modulation of suprachiasmatic-nucleus activity in some research designs. This places DSIP in the circadian-modulator research literature alongside other peptides that exhibit time-of-day-dependent expression patterns. The published corpus frames DSIP as a candidate circadian-modulator rather than a clock-resetting agent — the research documents correlations and effects on circadian endpoints, not a single resolved circadian-pacemaker mechanism.

Stress-axis modulation

One of the better-replicated DSIP research findings is its effect on the HPA (hypothalamic-pituitary-adrenal) stress axis. Published research documents DSIP-induced reductions in corticosterone elevation in stress-research designs in research-animal models [6]. The mechanism appears to involve modulation of hypothalamic releasing-factor signaling and pituitary corticotrope output, although the precise receptor target has not been fully characterised. The HPA-axis research line is one of the more consistent DSIP findings across labs and research-design generations.

Antioxidant and neuroprotective effects

A distinct DSIP research line documents effects on lipid-peroxidation markers, mitochondrial-function endpoints, and neuroprotection in cerebral-ischemia models [3][4]. Russian-research-lineage publications have characterised DSIP effects on rat-brain mitochondria, oxidative-stress markers and ischemic-neuroprotection endpoints — a research line that parallels the broader Russian neuropeptide neuroprotection corpus around Selank and Semax.

Anti-convulsant research

A smaller but published research line documents DSIP effects in seizure-research models, attributed to general inhibitory-system modulation rather than a single anticonvulsant target. This research line is consistent with the broader picture of DSIP as a multi-system bioelectric-activity modulator rather than a single-mechanism compound.

Sleep-architecture research literature

Published research-animal-model literature on DSIP and sleep documents several distinct endpoints: increased delta-wave power during NREM sleep, modulation of sleep-spindle frequency, and effects on sleep-onset latency in research-animal protocols. These endpoints have appeared with varying consistency across research groups and across decades of work.

Honest framing matters here. The original 1977 delta-sleep-inducing claim has been moderated by the modern published literature into something closer to “modulator of sleep architecture” — DSIP is documented in published research to influence sleep-stage parameters, but the strong original claim that DSIP plasma levels primarily drive delta-sleep onset has not been fully reproduced [2]. The contemporary research positioning is that DSIP is one of several modulatory factors involved in sleep-architecture regulation, not the singular delta-sleep trigger that the historical name implies.

Russian research lineage

DSIP has been investigated extensively in Russian research literature, alongside Selank, Semax and other neuropeptides at the Institute of Molecular Genetics of the Russian Academy of Sciences and related Russian institutes. The Russian DSIP research corpus has investigated stress, sleep, neuroprotective and oxidative-stress endpoints, with publications spanning the 1980s through the present.

This research is part of the published peer-reviewed literature, but its regulatory framing is distinct from the FDA / EMA drug-approval pathway. The material referenced in this guide is research literature — not therapeutic recommendation. The Russian DSIP research lineage parallels the Selank and Semax research programmes in the same institutional ecosystem and methodological tradition.

Selank, Semax, DSIP — Cognitive Stack neuropeptide trio

DSIP completes the three-compound Cognitive Stack alongside Selank and Semax. The three peptides cover three non-overlapping neuropeptide research mechanisms — that is the design rationale for combining them in a single research stack.

Compound	Mechanism class	Research line
Selank	Anxiolytic / GABAergic / immune-modulation (tuftsin-derived)	Anxiolytic + immune research
Semax	BDNF / NGF / cognitive-enhancement / cerebral-ischemia (ACTH-derived)	Cognitive + neuroprotection research
DSIP	Multi-system modulator / sleep-architecture / stress-axis	Sleep + stress + circadian research

The three compounds occupy distinct mechanism categories. Selank’s GABAergic / anxiolytic research line, Semax’s BDNF / cognitive corpus and DSIP’s sleep-architecture / stress-axis literature are non-overlapping — that is what makes the Cognitive Stack a coherent three-compound research design rather than a redundant pairing.

Storage and handling

DSIP ships as lyophilized powder. Standard research-handling literature documents:

• Lyophilized state: sealed at −20°C, protected from light. Stable for the manufacturer-stated window (typically 24+ months).
• Diluent: bacteriostatic water (0.9% benzyl alcohol) is the standard reconstitution diluent for research-grade peptide handling.
• Reconstituted state: refrigerate at 2–8°C. Use within ~28 days under refrigeration.
• Avoid freeze-thaw cycles after reconstitution — repeated freezing and thawing degrades peptide integrity.
• Light protection: store the reconstituted vial in an opaque or amber container, away from prolonged light exposure.

Each TogoPeptide DSIP shipment includes a per-batch Certificate of Analysis with HPLC purity (target ≥98%), mass-spectrometry identity confirmation, lot number, manufacture date, analysis date. See how to read a COA or reconstitution methodology for the methodology details.

Cross-research lines and pairings

• Cognitive Stack — Selank + Semax + DSIP: the curated three-compound research stack pairs Selank’s anxiolytic / GABAergic mechanism with Semax’s BDNF / cognitive corpus and DSIP’s sleep-architecture and stress-axis research line. The canonical Russian-research-line neuropeptide trio combination in published cognitive-research designs.
• Reconstitution math: DSIP ships at 5 mg per vial. Stock and target concentrations are documented in the reconstitution calculator.
• Stress + sleep cross-research: the HPA-axis and sleep-architecture research lines overlap mechanistically — DSIP is one of the few research peptides positioned at the intersection of these two endpoint families in the published literature.

Closing

DSIP is a 9-amino-acid nonapeptide (WAGGDASGE) originally isolated in 1977 by Schoenenberger and Monnier from rabbit cerebral venous blood during electrically-induced delta-sleep states. The compound’s name reflects that original isolation assay, but decades of subsequent published research have established DSIP as a multi-system neuromodulator with documented effects on sleep architecture, circadian rhythm, HPA stress-axis, oxidative stress and neuroprotection — rather than as a single-mechanism hypnotic factor. DSIP completes the Cognitive Stack alongside Selank and Semax as the third Russian-research-line neuropeptide covering sleep and stress endpoints.

This guide documents what published peer-reviewed research has investigated. It is mechanism context for laboratory researchers, not therapeutic recommendation, not protocol guidance, not a basis for self-administration of any kind.

Source DSIP for laboratory research:

• DSIP product page — full identifiers, 5 mg vial, per-batch COA
• Cognitive Stack — curated three-compound research stack (Selank + Semax + DSIP)
• Cognitive research compounds — full category listing

For methodology and laboratory-handling questions, contact our research-supply team at info@togopeptide.com.